Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-01-10
2008-11-18
Berch, Mark L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S263230, C544S265000, C544S277000
Reexamination Certificate
active
07452894
ABSTRACT:
Use of a compound of formula (I) wherein R1is selected from alkyl, aryl, alkoxy, aryloxy, 0thioalkyl, thioaryl, CN, halo, NR5R6, NR4COR5, NR4CONR5R6, NR4CO2R7and NR4SO2R7; R2is selected from N, O or S-containing heteroaryl groups, wherein the heteroaryl group is attached via an unsaturated carbon atom which is adjacent to one or two N, O or S-heteroatom(s), other than ortho, ortho-disubstituted heteroaryl groups; R3is selected from H, alkyl, COR8, CONR9R10, CONR8NR9R10, CO2R11and SO2R11; R4, R5and R6are independently selected from H, alkyl and aryl or where R5and R6are in an (NR5R6) group then R5and R6may be linked to form a heterocyclic ring; R7is selected from alkyl and aryl; R8, R9and R10are independently selected from H, alkyl and aryl, or R9and R10may be linked to form a heterocyclic ring, or where R8, R9and R10are in a (CONR8NR9R10) group, R8and R9may be linked to form a heterocyclic group; and R11, is selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2Areceptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or for neuroprotection in a subject; compounds of formula (I) for use in therapy; and novel compounds of formula (I) per se.
REFERENCES:
patent: 6197788 (2001-03-01), Fletcher et al.
patent: 6583156 (2003-06-01), Gillespie et al.
patent: 6608085 (2003-08-01), Gillespie et al.
patent: 6787541 (2004-09-01), Gillespie et al.
patent: 0 992 510 (2000-04-01), None
patent: 1 221 444 (2002-07-01), None
patent: 1 300 147 (2003-04-01), None
patent: WO 94/17803 (1994-08-01), None
patent: WO 99/01454 (1999-01-01), None
patent: WO 99/48903 (1999-09-01), None
patent: WO 01/02400 (2001-01-01), None
Wolff, Manfred E. “Burger's Medicinal Chemistry, 5ed, Part I”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G. S. et al, “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, pp. 451 and 596.
Kulisevsky, Jaime; Barbanoj, Manel; Gironell, Alexandre; Antonijoan, Rosa; Casas, Miquel; Pascual-Sedano, Berta, Clinical Neuropharmacology. 25(1):25-31, Jan./Feb. 2002, abstract only.
Morelli, Micaela, Experimental Neurology, 184, 20-23, 2003.
Tuite, Paul et al, Expert. Opin. Investig. Drugs, 12, 1335-1352, 2003.
Bibbiani, F. et al, Experimental Neurology, 184, 285-294, 2003.
Spiros Konitsiotis, Expert. Opin. Investig. Drugs, 14, 377-392 2005.
Anonymous, Drug and Therapeutic Bulletin, 35, pp. 36-40, 1999.
LeWitt, Peter A., Pharmacotherapy, 20, pp. 26S-32S, 2000.
Weiss, S. M.; Benwell, K.; Cliffe, I. A.; Gillespie, R. J.; Knight, A. R.; Lerpiniere, J.; Misra, A.; Pratt, R. M.; Revell, D.; Upton, R.; Dourish, C. T., Neurology, 61(11, Suppl. 6), S101-S106 (English) 2003.
Hirao, Ichiro; Mitsui, Tsuneo; Kimoto, Michiko; Harada, Yoko; Yokoyama, Shigeyuki, Nucleic Acids Research Supplement, 3(3rdIternational Symposium on Nucleic Acids Chemistry [and] 30th Symposium on Nucleic Acids Chemistry in Japan, 2003), 215-216.
Akira Matsuda, “Invitation”, Hokkaido University, Sapporo Japan, [online] Nov. 18, 2004, [retrieved on Jul. 21, 2005]. Retrieved from the Internet, <http://www.hokudai.ac.jp/pharma/yakka/inacs.html>.
Loscher W.,.Epilepsy Res. Jun. 2002;50(1-2):105-23.
Jennifer L. Hellier, Peter R. Patrylo, Ping Dou, Michelle Nett, Gregory M. Rose, and F. Edward Dudek, J. Neurosci. 1999, 19(22):10053-10064.
Wenning GK, Granata R, Puschban Z, Scherfler C, Poewe W., .J Neural Transm Suppl. 1999;55:103-13, Medline abstract PMID: 10335497.
Rebecca J. Carter et al ,The Journal of Neuroscience, Apr. 15, 1999, 19(8):3248-3257.
Yanamoto H, Nagata I, Niitsu Y, Xue JH, Zhang Z, Kikuchi H., Evaluation of MCAO stroke models in normotensive rats: standardized neocortical infarction by the 3VO technique, Exp Neurol. Aug. 2003;182(2):261-74.
Osborne NN, Chidlow G, Layton CJ, Wood JP, Casson RJ, Melena J., Optic nerve and neuroprotection strategies.Eye. Nov. 2004;18(11):1075-84.
Jenner, Peter, Expert Opin. Investig. Drugs, 14(6), 2005, pp. 729-738.
McKenzie, Thomas C. and Epstein, Joseph W., J. Org. Chem., 47, 1982, 4881-4884.
Alarcon et al., “Diaminoupurine-acridine Heterodimers for Specific Recognition of Abasic Site Containing DNA. Influence on the Biological Activity of the Position of the Linker on the Purine Ring,”Bioorg. Med. Chem. Lett. (2001), vol. 11, pp. 1855-1858, XP002192660.
Alarcon et al., “2-Amino-6-(1,2,4-triazol-4-yl)-purine: a useful intermediate in the synthesis of 9-alkylguanines,”Tetrahedron Letters(2000), vol. 41, pp. 7211-7215, XP002192661.
Gunderson, “6-Chlorpuines and Organostannanes in Palladium Catalyzed Cross Coupling Reactions,”Tetrahedron Letters(1994), vol. 35, No. 19, pp. 3155-3158, XP001061830.
Skalski et al., “Photophysical properties of pyridinlum salts derived from purine bases,”Can J. Chem. (1990), vol. 68, No. 12, pp. 2164-2170, XP001061835.
Jaskolski et al., “Structure of N-(2-Amino-6-purinyl) pyridinium Chloride Dihydrate,”Acta Cyrstallogr., Sect. C: Cryst. Struct. Commun. (1987), vol. C43, No. 11, pp. 2110-2113, XP001058066.
Strappaghetti et al., “Adenosince receptors: synthesis, structure-activity relationships and biological activity of new 6-amino purine derivatives,”Eur. J. Med. Chem. (1998), vol. 33, pp. 501-508, XP002192662.
Cesnek, et al., Collect. Czech. Chem. Commun., (2000), pp. 1357-1373, 65(9).
Bakkestuen, et al., Bioorg. Med. Chem. Lett. (2000), pp. 1207-1210, 10(11).
Hocek, et al., Collect. Czech. Chem. Commun. (1997), pp. 136-146 61(1).
Langll, et al., Tetrahedron, (1996), pp. 5625-5638, 52(15).
McKenzie, et al., J. Org. Chem. (1982), pp. 4881-4884, 47(25).
Nair, et al., J. Org. Chem. (1982), pp. 4520-4524, 47(23).
Muresan, et al., Theochem (1995), pp. 161-171, 342.
Nair, et al., J. Org. Chem. (1984), pp. 4340-4344, 49(23).
Havelkova, et al., Synlett, (1999), pp. 1145-1147, (7).
Nolsoe, et al., Acta Chem. Scand. (1999), pp. 366-372, 53(5).
Gundersen, Acta Chem. Scand, (1996), pp. 462-465, 50(5).
Estep, et al., J. Med. Chem., (1995), pp. 2582-2595, 38(14).
Gundersen, et al., Tetrahedron Lett., (1995), pp. 1945-1948, 36(11).
Gundersen, et al., Tetrahedron, (1994), pp. 9743-9756, 50(32).
Nair, et al., Magn. Reson. Chem., (1987), pp. 937-940, 25(11),.
Robev, et al., Dokl. Bolg. Akad. Nauk, (1978), pp. 1131-1134, 31(9).
Prasad, et al., Tetrahedron, (1997), pp. 7237-7254, 53(21).
Stevenson, et al., Tetrahedron Lett., (1996), pp. 8375-8378, 37(46).
Hamamichi, et al., Heterocycles, (1990), pp. 321-326, 31(2).
Hamamichi, et al., J. Heterocycl. Chem., (1990), pp. 835-838, 27(4).
Pendergast, et al., J. Chem. Soc. Perkin Trans. 1, (1973), pp. 2759-2763, (22).
Kim, et al., Arch. Pharmacal Res., (1998), pp. 458-464, 21(4).
(Abstract only) Bailey et al., “Changes in spinal δ- and κ-opioid systems in mice deficient in the A2A receptor gene”,Journal of Neuroscience, vol. 22, No. 21, 2002 (pp. 9210-9220).
(Abstract only) Bara-Jimenez et al., “Adenosine A2A receptor antagonist treatment of Parkinson's disease”,Neurology, vol. 61, No. 3, 2003 (pp. 293-296).
Bastia et al., “Effects of A1and A2Aadenosine receptor ligands in mouse acute models of pain”,Neuroscience Letters 328, 2002 (pp. 241-244).
Behan et al., “Enhanced neuronal damage by co-administration of quinolinic acid and free radicals, and protection by adenosine A2Areceptor antagonists”,British Hournal of Pharmacology, vol. 135, 2002 (pp. 1435-1442).
Bertorelli et al., “Effects of Selective Agonists and Antagonists for A1or A2AAdenosine Receptors on Sleep-Waking Patterns in Rats”,Drug Development Research, vol. 37, 1996 (pp. 65-72).
(Abstract only) Chase et al., “Translating A2Aantagonist KW6002 from animal models to parkinsonian patients”,N
Dawson Claire Elizabeth
Gaur Suneel
Gillespie Roger John
Lerpiniere Joanne
Pratt Robert Mark
Berch Mark L
Foley & Lardner LLP
Vernalis Research Limited
LandOfFree
Purine derivatives as purinergic receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Purine derivatives as purinergic receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purine derivatives as purinergic receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4042647